Boston Sci prevails in lawsuit over sales group

Boston Scientific ($BSX) has scored a win in a Boston court with the dismissal of a class-action lawsuit alleging it had failed to disclose questionable sales practices to investors. The decision comes a year after four pension funds filed suit claiming they had lost more than $2.8 million from buying the company's stock at an artificially inflated price. In his decision, U.S. District Judge Douglas Woodlock said the pension funds' complaint failed to state a "cognizable" claim for securities fraud, Bloomberg notes. Story 

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.